Vinay M. Daryani

Denali Therapeutics Inc.

Poster(s):

• P-046 - WITHDRAWN - LRRK2 INHIBITION BY BIIB122/DNL151 SUPPORTS EXPOSURES ACHIEVING ROBUST TARGET AND LYSOSOMAL ENGAGEMENT IN PARKINSON’S PATIENTS: A TRANSLATIONAL PK-PD APPROACH.

• P-047 - WITHDRAWN - MODEL INFORMED DEVELOPMENT OF LRRK2 INHIBITOR DNL201 IN PARKINSON’S DISEASE: A POPPK-PD APPROACH FOR DOSE SELECTION WITH A SUSTAINED RELEASE (SR) FORMULATION.